Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Magnesium oxide
Drug ID BADD_D02442
Description Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.
Indications and Usage Indicated for over-the-counter use as a supplement for cardiovascular and neuromuscular health, and as an antacid for relief of acid indigestion and upset stomach.
Marketing Status approved
ATC Code A02AA02; A06AD02; A12CC10
DrugBank ID DB01377
KEGG ID D01167
MeSH ID D008277
PubChem ID 14792
TTD Drug ID Not Available
NDC Product Code 12784-437; 50917-857; 54738-973; 69367-298; 0603-0213; 54738-974; 71610-172; 71610-182; 0603-0209; 83335-001; 10135-721; 24689-132; 50917-887; 58657-120; 63629-1126; 50917-837; 63629-2217; 63629-9420; 68210-4171; 71335-1960; 50917-867; 50917-877; 55570-280
UNII 3A3U0GI71G
Synonyms Magnesium Oxide | Oxide, Magnesium | Magnesia
Chemical Information
Molecular Formula MgO
CAS Registry Number 1309-48-4
SMILES O=[Mg]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Salivary hypersecretion07.06.01.0090.000182%Not Available
Skin lesion23.03.03.0100.000182%Not Available
Somnolence19.02.05.003; 17.02.04.0060.000274%
Subarachnoid haemorrhage12.01.10.011; 24.07.04.004; 17.08.01.0100.000274%Not Available
Thrombocytopenia01.08.01.0020.000274%Not Available
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.0060.000182%
Urinary retention20.02.02.0110.000365%
Vomiting07.01.07.0030.000948%
Balance disorder08.01.03.081; 17.02.02.0070.000182%Not Available
Malnutrition14.03.02.0040.000182%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.001003%
Disease progression08.01.03.0380.000274%
Drug intolerance08.06.01.0130.000620%Not Available
Renal impairment20.01.03.0100.000456%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000182%Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.000274%
Acute kidney injury20.01.03.0160.001824%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000182%Not Available
Milk-alkali syndrome14.01.02.0050.000182%Not Available
Chronic myeloid leukaemia transformation16.01.07.004; 01.10.07.0040.000182%Not Available
The 3th Page    First    Pre   3    Total 3 Pages